Study: Experimental Alzheimer’s drug slows decline.
- Drugmaker Eli Lilly says it has made a major breakthrough in treatment for Alzheimer’s disease and is planning to submit its drug for the Food and Drug Administration’s approval next month.
In a clinical trial, the company’s medicine Donanemab found progression of the disease slowed by 35% over the course of 18 months.It travels to the brain and finds and binds plaques linked to Alzheimer’s.According to Eli Lilly, about half of the patients achieved plaque clearance after one year and 72% achieved it in 18 months.Copyright 2023 CNN Newsource. All rights reserved.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Experimental Drug Slows Alzheimer’s in Large Study, Eli Lilly SaysAn experimental Eli Lilly drug slowed cognitive and functional decline for people with early-stage Alzheimer’s disease in a new study that could support regulatory approval and commercial sale
Leer más »
Eli Lilly's Alzheimer's drug donanemab slows cognitive decline: trialAn experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly
Leer más »
Eli Lilly's diabetes drug could revolutionize the US weight loss marketEli Lilly’s diabetes drug delivers promising results in a recent clinical trial. The company hopes it will be added to the U.S. weight loss market soon.
Leer más »
The Book Of Eli Ending & Meaning ExplainedThe post-apocalyptic action movie The Book of Eli features a surprise twist ending that leaves audiences with a lot of unanswered questions.
Leer más »
Eli Lilly Alzheimer’s treatment donanemab slowed disease progression in clinical trialDonanemab, a monthly antibody infusion made by pharmaceutical company Eli Lilly, also significantly reduced brain plaque associated with Alzheimer's disease.
Leer más »
Man admits he robbed financial services company of more than $1MEli Schamovic, 41, of Lakewood, pleaded guilty to money laundering in U.S. District Court.
Leer más »